1. Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells
- Author
-
Eun Seong Jo, Kyoung-Jin Jang, Nipin Sp, Dong Young Kang, Jin-Moo Lee, Se Won Bae, and Alexis Rugamba
- Subjects
0301 basic medicine ,Lung Neoplasms ,non-small cell lung cancer (NSCLC) ,Apoptosis ,NSCLC ,B7-H1 Antigen ,chemistry.chemical_compound ,0302 clinical medicine ,Cell Movement ,Carcinoma, Non-Small-Cell Lung ,STAT5 Transcription Factor ,Epidermal growth factor receptor ,Biology (General) ,Promoter Regions, Genetic ,tumorsphere ,biology ,Chemistry ,General Medicine ,ErbB Receptors ,030220 oncology & carcinogenesis ,Disease Progression ,Neoplastic Stem Cells ,Protein Binding ,PD-L1 ,QH301-705.5 ,EGFR ,Silibinin ,Neovascularization, Physiologic ,JAK2/STAT5b ,Models, Biological ,Article ,03 medical and health sciences ,Cell Line, Tumor ,Spheroids, Cellular ,medicine ,Human Umbilical Vein Endothelial Cells ,Humans ,Neoplasm Invasiveness ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,silibinin ,PI3K/AKT ,Cell growth ,Cancer ,Cell Cycle Checkpoints ,medicine.disease ,030104 developmental biology ,Tumor progression ,Silybin ,Cancer research ,biology.protein ,MMP2 - Abstract
Recently, natural compounds have been used globally for cancer treatment studies. Silibinin is a natural compound extracted from Silybum marianum (milk thistle), which has been suggested as an anticancer drug through various studies. Studies on its activity in various cancers are undergoing. This study demonstrated the molecular signaling behind the anticancer activity of silibinin in non-small cell lung cancer (NSCLC). Quantitative real-time polymerase chain reaction and Western blotting analysis were performed for molecular signaling analysis. Wound healing assay, invasion assay, and in vitro angiogenesis were performed for the anticancer activity of silibinin. The results indicated that silibinin inhibited A549, H292, and H460 cell proliferation in a concentration-dependent manner, as confirmed by the induction of G0/G1 cell cycle arrest and apoptosis and the inhibition of tumor angiogenesis, migration, and invasion. This study also assessed the role of silibinin in suppressing tumorsphere formation using the tumorsphere formation assay. By binding to the epidermal growth factor receptor (EGFR), silibinin downregulated phosphorylated EGFR expression, which then inhibited its downstream targets, the JAK2/STAT5 and PI3K/AKT pathways, and thereby reduced matrix metalloproteinase, PD-L1, and vascular endothelial growth factor expression. Binding analysis demonstrated that STAT5 binds to the PD-L1 promoter region in the nucleus and silibinin inhibited the STAT5/PD-L1 complex. Altogether, silibinin could be considered as a candidate for tumor immunotherapy and cancer stem cell-targeted therapy.
- Published
- 2021